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Abstract. Severe memory impairment forms the core symptom of Alzheimer’s disease (AD), which is present early in the disease
course. Recent studies show that AD patients not only suffer from forgetfulness, but also differ in their response bias, when having
to decide whether information has been perceived recently, or whether it is only familiar or semantically related to perceived
information. Changes in total tau-protein and amyloid-β (Aβ)1−42 concentration in cerebrospinal fluid are also features of AD,
and they predict conversion from mild cognitive impairment to dementia. In this study we correlated recognition scores with
total tau and Aβ1−42 concentrations in patients with suggested dementia. We studied 40 patients and 21 healthy controls, using
an incidental recognition memory task and a neuropsychological test battery. False recognition scores correlated with delayed
recall and with Aβ1−42, and Aβ1−42 tended to correlate with delayed recall. Total tau, however, did not correlate with memory
scores or with neuropsychological performance in general. We suggest that Aβ1−42 may indicate a reduction in the specificity
of the neuronal response in the limbic cortex, due to agglomeration of plaques. This process might be more specific for AD than
the increase of tau, and therefore it is stronger correlated with recognition errors.
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INTRODUCTION
Alzheimer’s disease (AD) is the most common type
of dementia and the risk of AD is rising, due to increas-
ing life expectancy. The earliest and core symptom
of AD is an episodic memory deficit, which starts to
aggravate during the preclinical period [1], and is ac-
companied by increasingly severe disturbances in lan-
guage, attention, executive functions, and mood in later
phases of the disease [2,3]. More specifically, AD is
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characterized by impairment in delayed recall, and sev-
eral studies have shown that this impairment is a sensi-
tive and partly specific feature for patients converting
from mild cognitive impairment to AD [4–7]. There-
fore, neuropsychological assessment of AD in an early
phase crucially depends on learning tests and on recall
of to-be-learned information after a delay or following
interfering information [8–10].
Recently, it has been argued that a bias to accept
seemingly familiar information as actually perceived or
learned might be another specific feature of the memory
impairment in AD. Typically, AD patients tend to pro-
duce more false positives on recognition tests as con-
trols, especially in response to pictures showing high
frequent and meaningful objects [11–15]. They seem
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to base their decision, whether an item has been pre-
sented before, not so much on recollection of that item,
but rather on a feeling of familiarity. Consequently,
they accept semantically related items as target items
on recognition tests. This increase in false positives
has also been found in clinical studies using the Cal-
ifornia Verbal Learning Test [16–18], which contains
semantically related lures in the recognition part.
Several explanations for this increase of intrusions
in AD have been proposed [15]. It might be a conse-
quence of a generally more liberal response bias, a ten-
dency to accept all information as learned information.
It might also be a consequence of the episodic memory
impairment, in which the feeling of familiarity remains
as the primary basis for recognition, while recollection
is disturbed. The increase in recognition errors thus
indicates something like a compensation of the repro-
duction deficit itself. And, as a third explanation, en-
coding of item specific information, rather than the gist
(of the general semantic features), might be specifically
impaired in AD. Consequently, during recognition, AD
patients may base their decisions on gist information
and judge semantically related information as correct.
Although it is not clear which explanation is valid, the
finding of a high number of false positives in AD is
generally accepted [15].
Numerous studies have confirmed the decrease of
amyloid-β1−42 (Aβ1−42) and the increase of tau in
cerebrospinal fluid (CSF) in AD patients, and recent
reviews argue for a sensitivity and specificity of about
80% for each of these CSF markers in AD [19–24].
The underlying neuropathological changes in AD in-
clude degeneration of neurons and synapses in defined
regions of the brain and the formation of senile plaques
and neurofibrillary changes. Braak and colleagues [26,
27] have shown in postmortem studies that the con-
centration of senile plaques and neurofibrillary tangles
with intracellular tau proteins follows a more or less
fixed pathway, starting in the hippocampal and entorhi-
nal cortex, and spreading over the temporal cortex to
secondary and tertiary association areas. This origin in
the hippocampal and entorhinal cortex may be the com-
mon cause of decrease of Aβ1−42 and increase of total
tau in the CSF and of deficits in memory performance as
the first sign of a beginning AD. Senile plaques consist
of a protein core in which the main protein is Aβ1−42.
It has been argued that this is the reason why Aβ1−42
is reduced in the CSF of AD patients [28–30].
The Aβ theory of AD further states that the in-
crease of senile plaques leads to neuronal stress and
cell death, which in turn leads to higher extracellular
concentration of tau proteins, and thus to an increase
of tau in the CSF [28]. However, tau regulates intra-
cellular traffic of vesicles and it inhibits transport of
amyloid-β protein precursor (AβPP) into neuronal ex-
tensions, which leads to accumulation of AβPP in the
cell body [31]. One might speculate that this mecha-
nism plays a role in β- and γ-secretase of AβPP into
Aβ1−42 and therefore might lead to agglomeration in
plaques. On the other hand, many neurodegenerative
diseases, like, for instance, frontotemporal dementia
and dementia of Parkinson’s disease, show an elevat-
ed level of total tau, but no production of Aβ1−42 de-
posits [28]. Therefore, extracellular tau is not a causal
factor for agglomeration of plaques. Hence, the defi-
nite link between cell death and total tau concentration
in the CSF remains unclear. Irrespective of these con-
siderations, numerous studies have confirmed the de-
crease of Aβ1−42 and the increase of tau in AD patients,
and recent reviews argue for a sensitivity and specifici-
ty of about 80% for each of these liquor markers in
AD [32–34].
Surprisingly, the correlation of these CSF mark-
ers with neuropsychological tests has not been stud-
ied extensively. If any, these studies found significant
correlations with total tau concentration, but not with
Aβ1−42 [20,33,35,36]. Stomrud et al. [37], being an
exception to this rule, reported that in elderly people
low levels of Aβ1−42 correlate with subjective memory
complaints, and it predicts the decline of Mini Mental
Status Examination (MMSE) score three years later. A
similar prediction of faster conversion to AD in mild
cognitive impaired (MCI) patients with low concentra-
tion of Aβ1−42 in CSF has also been reported [20].
The few studies, that have been published, re-
lied on rather unsophisticated cognitive tests, like the
MMSE [33,35–37] (for an exception [20]). This in-
strument yields a composite score of cognitive impair-
ment and entails only one episodic memory test (test-
ing short-delayed free recall of three words), using a
single learning presentation. Moreover, it provides on-
ly a global score for classifying patients into groups
with a weak, moderate or severe dementia. Therefore,
the MMSE is neither sensitive, nor specific for detect-
ing memory deficits in individuals with MCI or early
stages of AD. Nevertheless, the lack of correlation is
surprising because CSF markers have a moderate to
high sensitivity and specificity for AD, predict conver-
sion from preclinical impairment to dementia and neu-
ropsychological screening of dementia often relies on
the MMSE.
In this study, we analyzed memory performance and
the correlation with total tau and Aβ1−42 in the CSF
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of patients, who had been admitted to the neurologi-
cal department of our hospital with different neurolog-
ical symptoms, but they all had a common subjective
complaint of cognitive (memory) decline or a report of
cognitive deficits by relatives. The reason for inclusion
of patients with different forms of dementia was to en-
sure that variation in the CSF concentration of tau and
Aβ1−42 was large enough to find a differential correla-
tion with omissions and false positives in recognition.
We developed an easy and short test, based on inci-
dental learning, for provoking recognition errors. Fol-
lowing Budson and colleagues [11–14], we postulated
that an increase of false positives is a specific feature of
the memory impairment in AD, and it should correlate
with CSF markers.
MATERIALS AND METHODS
Patients
We examined 40 patients, admitted over the last two
years to the neurological department of the Hospital
Bremen-Ost for cognitive, and partly for additional mo-
tor impairments. See for demographic details Table 1.
Patients with definite other causes for their impairment,
like inflammation or acute stroke, were excluded from
the study. The clinical diagnosis recorded was based
on best clinical judgment using the diagnostic crite-
ria of ICD 10, but blind with respect to the results of
experimental recognition testing (see below).
Four patients were cognitively unimpaired (based on
an MMSE score higher than 28), 13 patients showed a
mild cognitive impairment (MMSE range 25–28), 15
mild dementia (MMSE range 18–24), 7 moderate de-
mentia (MMSE range 10–17), and 1 patient severe de-
mentia (MMSE = 8). The final diagnosis was for 11
patients probable AD, for 14 patients preclinical AD or
MCI, for 9 patients dementia, but not necessarily AD
(vascular dementia or frontotemporal dementia were
discussed as alternative diagnosis), and for the remain-
ing 6 patients either normal pressure hydrocephalus,
vascular dementia or frontotemporal dementia. Ac-
cording to the criteria for MCI [38], 10 of the MCI
patients were of the amnestic type, 3 of a multi-domain
type and 1 of a non-amnestic type.
Twenty-one healthy control subjects were recruited
and they received the same neuropsychological tests
as the patients (but no neurological examination and
no lumbar puncture). Controls were contacted in vari-
ous forms, for example, by asking relatives of patients,
hand-outs in meetings of elderly people and by con-
tacting friends of parents. The project was approved by
the Ethics committee of the University of Oldenburg,
and all subjects gave informed consent to participate in
the project.
Investigation of false recognition
Participants were presented 16 pictures from the
Snodgrass & Vanderwart series [39] and they were
asked to name them. They were not informed that
they would be asked to recognize them later. After 15
minutes, the recognition test was presented, consisting
of 24 trials. We used the Beck-Depressions-Inventory
(BDI) [40] and the Zahlenverbindungstest [41] as filler
tests for the period between the presentation of the pic-
tures and the recognition task.
In the recognition task, on each trial, 3 different pic-
tures were shown simultaneously. The three pictures
were semantically related to each other (pictures of
similar animals, similar furniture, etc.). On 8 trials,
only new pictures were shown; on 16 trials an ‘old’ pic-
ture was shown, together with 2 distractors. The par-
ticipants were asked to indicate whether they had seen
one of these before, and if so, which picture, by point-
ing to it or naming it. If they decided incorrectly that
none of the three pictures had been presented before,
we counted this as an omission. If they pointed to a
picture that had not been shown before, we counted this
as a false positive. We used the number of omissions
as indication of increased forgetting and the number of
false positive errors as indication of false recognition.
Neuropsychological investigation
All patients underwent a neuropsychological exam-
ination, including the CERAD test series [42], which
is composed of the MMSE, a 15-item short version of
the Boston Naming Test, semantic word fluency test
for animals (one minute), word list learning (10 words,
three trials), word list recall after distraction, word list
recognition (10 target and 10 distractor words), figure
copying and delayed figure recall.
To explore language functioning even further, we
used first-letter fluency from the Leistungspru¨fsystem
50+ (Performance test) [43], which is a German ver-
sion of the FAS test, comprising the generation of words
with three different first letters, each for one minute.
The Mehrfachwahl-Wortschatz-Intelligenztest (Multi-
ple Choice Vocabulary Intelligence Test) [44] was per-
formed as a measure for extent of and access to the vo-
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Table 1
Demographic data, CSF marker, results from the recognition task
Patient group Controls
N 40 21
Male/female 24/16 11/10
Mean SD Mean SD
Age 69.4 8.6 66.1 13.1
Education in years 13.0 3.0 13.5 4.1
Mini Mental Status Examination∗∗ 22.1 6 29.5 1
Total tau 407.5 250.1 − −
Amyloid-β1−42 706.8 340.2 − −
Recognition task – omissions∗∗ 2.7 2.5 0.3 0.5
Recognition task – false positives∗∗ 2.4 2.4 0.3 0.5
∗∗p < 0.01
cabulary. To assess attention performance, we used the
Zahlenverbindungstest of the NAI [41], which is simi-
lar to the Trail Making Test A. Participants have to fol-
low numbers from 1 to 30 and to connect them by draw-
ing a line. We used digit span forwards and backwards
from the Wechsler Memory Scale (revised) [45] to in-
vestigate verbal working memory performance. The
Beck’s Depression Inventory [40] was used to investi-
gate mood and depression.
Neurological investigation
The standard diagnostic examination protocol in-
cluded medical history, physical and neurological ex-
amination, laboratory testing, brain imaging, electroen-
cephalography (EEG) and a lumbar puncture.
The extensive blood sample analysis included blood
count, erythrocyte sedimentation rate, electrolytes
(sodium, potassium, chloride), creatine, urea, transam-
inases, blood glucose, TSH, C-reactive protein, vita-
min B 12, folic acid. Optional further blood analyses
included vitamins, TPPA, immunological parameter,
HIV, copper metabolism, etc. An MRI/CT scan was
performed for every patient to exclude other causes for
cognitive impairment like strokes, tumors or inflamma-
tory diseases.
Determination of tau protein and Aβ1−42 in CSF
Lumbar punctures were performed between lumbar
vertebral body 4 and 5, by a trained neurologist, us-
ing a 22-gauge Sprotte spinal needle. Approximately
5 ml CSF was collected in polypropylene tubes and
transported to an adjacent laboratory within 30 min.
CSF samples were analyzed for cell count, total pro-
tein, lactate, glucose, IgG, IgA, IgM, Borrelioses an-
tibodies, Aβ1−42 and total tau. Except the specimen
for the cell count, some CSF was briefly centrifuged
at low speed (4000 rpm for 7 minutes) to pellet any
cellular elements, stored at a temperature of 4◦C (un-
frozen) and analyzed within 7 days. CSF total tau and
Aβ1−42 were determined quantitatively using commer-
cial sandwich enzyme-linked immunosorbent assays
(Innotest hTAU-Ag, Innotest Aβ1−42, Innogenet-
ics, Ghent, Belgium). All tests of Aβ1−42 and total tau
were performed at the Medizinisches Labor Bremen
(Dr. A. Gerritzen) according to the recommendations
of the manufacturer Innogenetics.
Statistical evaluation
As expected, the number of false positives and omis-
sions was low in the control subjects and also in some
of the patients. Consequently, the distribution of the
recognition scores was skewed, and we used the non-
parametric Spearman rank correlation for correlating
cognitive scores to the CSF-markers. Group differ-
ences in memory scores were tested with the Mann-
Whitney U-Test.
RESULTS
Demographic data
There were no significant differences in age, gen-
der and education between the patients and the healthy
controls.
CSF and recognition tests
Total Tau was, on average, 407.5 ng/l, Aβ1−42 706.8
ng/l, but clearly there was a wide range for both vari-
ables (see Table 1).
Patients omitted, on average, 2.7 items and produced
2.4 false positives. Compared to the performance of the
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healthy control group, both results deviate significantly
at p < 0.001 on the Mann-Whitney U-Test. The z-score
for omitted items was−5.13, that of false positives was
−4.48.
Neuropsychological testing
Patients’ mean performanceon each of the neuropsy-
chological tests was at least one standard deviation be-
low that of the healthy control group. Mann Whitney
U-tests revealed a significant p < 0.001 for all tests, ex-
cept word list Savings CERAD-NP and digit span for-
ward, where p < 0.05, and for intrusions from wordlist
learning of the CERAD-NP, which did not differ sig-
nificantly between groups.
Correlational analysis
No significant correlation was found between total
tau and Aβ1−42 [r: −0.111, p = 0.495]. Also, no cor-
relation was found between total Tau, age, education,
BDI and any of the neuropsychological scores. Aβ1−42
correlated significantly with the number of false pos-
itives in the experimental recognition test [r: −0.434,
p = 0.005], but not with omissions. The correlation
between Aβ1−42 and number of recalled items from
the Wordlist of the CERAD-NP was also significant [r:
0.354, p = 0.032], and also for the savings of word list
recall [r: 0.344, p = 0.04], for the number of recalled
figures from the figure drawing task [r: 0.359, p =
0.029] and savings from figure drawing recall [r: 0.374,
p = 0.023]. Moreover, Aβ1−42 correlated significantly
with processing time from the Zahlenverbindungstest
[r: −0.463, p = 0.007]. An exploratory analysis with
Pearson’s parametric correlation test did not yield other
results.
To analyze the meaning of Aβ1−42 in more detail,
we used a split-half method dividing the patient group
in patients with a relatively low and patients with a high
Aβ1−42 concentration. Patients with a low concentra-
tion (average Aβ1−42 concentration of 386.2 ng/l) pro-
duced 3.0 omissions and 3.3 false positives. Patients
with a high concentration (average Aβ1−42 concentra-
tion of 964.6 ng/l) produced 2.3 omissions and 1.4 false
positives. The difference for false positive errors but
not for omissions is significant (z: −2.360, p = 0.02).
The patient groups also differ in figure copying savings
[z: −2.227, p = 0.029] and in attention/psychomotor
speed [z: −2.187, p = 0.029].
The number of omissions in the recognition task was
correlated with several scores from the neuropsycho-
logical battery (see Table 2). Interestingly, omissions
were not correlated with word list recall of the CERAD-
NP, but a significant correlation was found with atten-
tion (Zahlenverbindungstest),digit span backwards and
copying performance of the CERAD-NP. On the other
hand, false positives in the recognition task did corre-
late with word list learning, word list delayed recall and
word list savings, i.e., with memory tasks and not with
executive tasks.
Analysis of sub-groups
As mentioned the clinical diagnosis was probable
AD for 11 patients, preclinical AD or mild cognitive
impairment for 14 patients, dementia, but not neces-
sarily AD for 9 patients, and for the remaining 6 pa-
tients either normal pressure hydrocephalus, vascular
dementia or frontotemporal dementia. Furthermore, to
examine the impact of different clinical diagnoses on
our results, we compiled three groups: patients with
probable AD, MCI patients and all other patients (not
AD dementia patients). Note that the inclusion of all
not probable AD patients into one group of not AD
dementia was done to have a reasonable group size, but
at the same time might have led to the inclusion of AD
patients in the not AD group.
The three groups did not differ significantly from
each other on tau and Aβ1−42 (probably because of the
small number of patients per group), although proba-
ble AD patients documented in absolute terms clearly
decreased level of Aβ1−42 (see Table 3). There were
also no significant correlations between false errors,
omissions and Aβ1−42 or tau in the single subgroups.
Comparing patients with probable AD and patients
with no definite indication for AD, the false positives in
recognition were significantly increased in AD patients
[z: −2.16, p = 0.035], but not the number of omissions.
Probable AD patients differed in false positive from
MCI patients [z: −2.031, p = 0.044], and in omitted
items [z: −2.080, p = 0.044]. MCI patients omitted
significantly fewer items than patients with no definite
indication for AD [z: −2.576, p = 0.012], but there
was no difference in false positives.
DISCUSSION
In this study, we concentrated on the question
whether recognition errors correlate with total tau or
Aβ1−42. Forty patients were recruited from our neu-
rological department with different diagnoses, but pri-
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Table 2
Rank correlation of omissions and false positives of the cognition task with neuropsy-
chological test results
Recognition task
Omissions False positives
Neuropsychological test results etc. Spearman r p Spearman r p
Recognition – false positives 0.307 0.054
Age 0.230 0.153 0.156 0.335
MMSE −0.336 0.042 −0.349 0.034
Zahlen-Verbindungs-Test 0.412 0.017 0.327 0.063
Digit span backwards −0.363 0.030 −0.091 0.597
CERAD-NP
Wordlist learning −0.346 0.036 −0.451 0.005
Wordlist recall −0.253 0.131 −0.485 0.002
Wordlist savings −0.174 0.311 −0.363 0.03
Copying performance −0.407 0.012 0.066 0.696
Only test scores with at least one significant correlation are shown. Figures in bold
and italics indicate correlations that are only significant for either omissions or errors.
Table 3
Subgroup characteristics
Probable AD Not AD dementia MCI Group differences
N 11 14 15
Mean SD Mean SD Mean SD
Age 68.5 11.0 72.1 5.0 67.8 9.0 ns
MMSE 16.7 5.5 21.4 3.9 26.1 2.9 pAD < NpAD < MCI
Tau 444.0 163.9 358.1 235.1 422.5 311.8 ns
Aβ 592.6 299.9 699.7 265.5 791.1 409.0 ns
Recognition – omissions 3.2 2.5 3.7 3.1 1.4 1.3 pAD = NpAD < MCI
Recognition false positives 3.5 2.4 1.6 1.6 2.1 2.8 pAD < NpAD = MCI
Abbreviations: AD = Alzheimer’s disease, MCI = Mild cognitive impairment, MMSE = Mini Mental State
Examination, SD = Standard deviation, pAD = Probable AD, NpAD = Not probable AD dementia.
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Fig. 1. Patients with high level concentration of Aβ1−42 did not differ from patient with low level concentration of Aβ1−42 in omissions but in
false positives of the recognition task. Both groups differed from healthy controls in either omissions and in false positives.
marily with deficits in memory and concentration, re-
ported by themselves or by their relatives. Most pa-
tients fulfilled the criteria of a preclinical AD, actually
classified as mild cognitively impaired, or they received
a diagnosis of a dementia with unclear aetiology (ICD-
10: F03). The heterogeneity of the final diagnoses of
our patients reflects the heterogeneity of patients admit-
ted to a neurological department for complaints about
cognitive functioning.
Aβ1−42 and total tau did not correlate in our patient
group. This may be a consequence of the small number
of patients. Unfortunately, most of the studies [23,37,
46] on liquor marker in AD do not report on the correla-
tion between these markers. One exception is the study
of Sunderland et al. [36], who investigated 131 patients
with AD and 72 controls. They found a correlation of
0.3 between Aβ1−42 and total tau, which is a weak to
moderate correlation. Interestingly, a separate analysis
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of the AD patients and the controls showed that only
in the controls the correlation was significant. In the
AD patients the correlation was−0.08, which is near to
zero. We conclude that total tau and Aβ1−42 measure
neuropathological changes, that are not closely linked
to each other, at least not in time. Hence, in principle,
deficits in different neuropsychological processes may
be associated with either an increase of total tau or a de-
crease of Aβ1−42 in the CSF, although both indicate a
neurodegenerative process resulting in global cognitive
decline and in dementia.
As far as we know, this is the first study reporting
a relation of cognitive performance with Aβ1−42, but
not with total tau in the CSF. Even more interestingly,
these correlations concerned primarily recognition er-
rors. This suggests that false recognition is sensitive
to neuropathological processes particularly associated
to a decrease of Aβ1−42 in CSF. Dividing the group
of patients in patients with high levels of Aβ1−42 and
patients with low levels, revealed two groups with ei-
ther a normal level or with a level, which is indicative
for AD (less than half of the level of the group with
high level of Aβ1−42, as defined by Blennow [34], and
also below a level of 400 ng/l as found by De Jong and
colleagues [22]). The group with a low level of Aβ1−42
differed from the group with a normal level of Aβ 1−42
concentration in false positives but not in omissions.
Splitting up the patients into subgroups with different
clinical diagnoses corroborated this result, because pa-
tients with probable AD differed from non-AD patients
and MCIs in false positives, but not in omissions.
The number of omissions on the recognition test cor-
relates with neuropsychological test scores like atten-
tion digit span backwards and copying performance
from CERAD-NP, indicating that this variable mea-
sures decline of cognitive functions related to execu-
tive functions rather than memory. False positives in
the recognition task, on the other hand, were correlated
with word list learning, word list recall, and word list
saving (all from the CERAD-NP). These scores con-
cern quite specifically memory, and they are known
to be particularly predictive for medio-temporal lobe
pathology and also for predicting Alzheimer demen-
tia [1,5,16]. Moreover, intrusions of CERAD word
list learning did not correlate with false positives from
the recognition task, and also neither with Aβ1−42.
This pattern of correlations suggests that two different
mechanisms causing errors may be distinguished and
that would argue against a globally increased liberal
response bias as an explanation for the higher number
of false recognitions in AD.
Schacter and Slotnick [47] related the fact that some
disorders result in a bias of relying on a feeling of famil-
iarity rather than on recollection of an episode during
recognition, to hippocampal pathology. This patholo-
gy, presumably, forces subjects to use non-hippocampal
structures for remembering events. The crucial sig-
nificance of the hippocampus for item-specific recall
(“recollection”) has been shown in patients with short
hypoxic episodes and isolated hippocampal lesions, but
also in fMRI-studies in healthy controls [48,49]. The
specific role cortical structures play in familiarity judg-
ment is still not fully understood, and there is a debate
about whether secondary and tertiary association areas
of the temporal, parietal and occipital lobe or the en-
torhinal cortex contribute to this process. What than
may be the explanation for the fact that Aβ1−42, and not
total tau, correlated with false positives in the recogni-
tion test? One may speculate that the accumulation of
plaques, adjacent to axons and dendrites of the limbic
system, diminish the specificity of neuronal responses,
leaving the general ability to respond intact [29,30]. In
this case, differential processing of information con-
tent is eliminated, while only the “general message”
of the information is stored or can be retrieved [28].
Tau pathology, on the other hand, may reflect func-
tional cell loss due to Aβ1−42 aggregation [29,30]. As
an indication of cell destruction, tau may be related
to a complete lack of retrieval and not of degrada-
tion of fine-grained information storage and retrieval.
Such an interpretation would explain the closer associ-
ation between total tau, the MMSE and the ADAS-cog
reported in the literature [20,31,33,37], compared to
Aβ1−42, because the MMSE and ADAS-cog measure
global cognitive impairment. In our study, this rather
weak correlation might not have shown up, because of
the relatively small number of patients. On the other
hand, the decrease of specificity of axonal and dendrite
processing starts earlier and is concentrated in the lim-
bic system. Therefore, the relation between recogni-
tion errors and Aβ1−42 might be close enough to be-
come significant already in a small group of patients.
This specific relation might also explain why decrease
of Aβ1−42 in CSF correlates with subjective memory
complaints [37], and also with decreased recall perfor-
mance (Table 2). Moreover, in the PET ligand study
of Pike and colleagues [50], memory impairment was
associated with enhancement of radiotracer in Aβ1−42
plaques, especially in the early stages of AD, i.e., in
MCI patients, but not in the later stages. This points in
the same directions as the explanation described above.
Clearly, this is somewhat speculative, and only fu-
ture studies can show, whether this line of reasoning is
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correct. For example, longitudinal studies of memory
performance and tau and Aβ1−42 concentration will be
necessary to corroborate the findings. Such longitu-
dinal studies would also be helpful to decide whether
there are different time courses in CSF changes (for ex-
ample, early decrease of Aβ1−42 and later increases of
tau). Our study used a cross-sectional design, which is
of limited value to investigate causal relations between
functional impairment and neurodegenerative process-
es. But from a clinical point of view, it seems to be
important to note that the close link between Aβ1−42
and recognition errors may enable us to screen patients
for a specific neurodegenerative process in an early
stage. Moreover, it would enable us to identify pa-
tients at risk with a fast, easily applicable and cheap in-
strument, namely a recognition test eliciting false pos-
itives, which may then be assessed with lumbar punc-
ture, to verify the indication from the cognitive evalu-
ation. But only future studies, including more subjects
with primarily a diagnosis of probable AD, will be able
to answer whether such a goal can be achieved.
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